Press Releases

Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).

Grünenthal certified as family-Grünenthal has once again been recognised for its commitment to improving the work-life balance of its employees. As part of the ‘berufundfamilie’ audit, the Aachen-based pharmaceutical company’s certificate has been extended for a further three years with a distinction.

Grünenthal announced today that the company successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist.

Grünenthal, a global leader in pain management and research, has published exceptional 2025 financial results, marking a year of record-high profitability and operational excellence.

Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza^®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.

Grünenthal today announced that it has acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, taking full ownership of the company formed through a joint venture and its portfolio of established medicines.

Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza¹, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain.

Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido^® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).¹

Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido^® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).¹

Grünenthal, a science-based pharmaceutical company and a leader in pain management, today announced the extension of its existing issue of Senior Secured Notes due 2031 (the “Existing Notes”) by €175 million (the “Additional Notes”) to a total sum of €675 million. The Additional Notes are expected to be issued and settled on 26 November 2025 (the “Issue Date”).